SG11201907925WA - Method of selecting for antibodies - Google Patents

Method of selecting for antibodies

Info

Publication number
SG11201907925WA
SG11201907925WA SG11201907925WA SG11201907925WA SG11201907925WA SG 11201907925W A SG11201907925W A SG 11201907925WA SG 11201907925W A SG11201907925W A SG 11201907925WA SG 11201907925W A SG11201907925W A SG 11201907925WA SG 11201907925W A SG11201907925W A SG 11201907925WA
Authority
SG
Singapore
Prior art keywords
oxford
international
antibodies
medawar
avenue
Prior art date
Application number
SG11201907925WA
Other languages
English (en)
Inventor
Ryan Cawood
Thomas Payne
Richard Parker-Manuel
Original Assignee
Oxford Genetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Genetics Ltd filed Critical Oxford Genetics Ltd
Publication of SG11201907925WA publication Critical patent/SG11201907925WA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5032—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on intercellular interactions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201907925WA 2017-03-15 2018-03-14 Method of selecting for antibodies SG11201907925WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1704115.3A GB201704115D0 (en) 2017-03-15 2017-03-15 Method of selecting for antibodies
PCT/GB2018/050645 WO2018167481A1 (fr) 2017-03-15 2018-03-14 Procédé de sélection d'anticorps

Publications (1)

Publication Number Publication Date
SG11201907925WA true SG11201907925WA (en) 2019-09-27

Family

ID=58605467

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907925WA SG11201907925WA (en) 2017-03-15 2018-03-14 Method of selecting for antibodies

Country Status (9)

Country Link
US (1) US20200072820A1 (fr)
EP (1) EP3596128A1 (fr)
JP (2) JP2020510438A (fr)
KR (1) KR102499955B1 (fr)
CN (1) CN110382548A (fr)
AU (1) AU2018234291A1 (fr)
GB (1) GB201704115D0 (fr)
SG (1) SG11201907925WA (fr)
WO (1) WO2018167481A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
JP2022524052A (ja) 2019-03-08 2022-04-27 オックスフォード ジェネティクス リミテッド 抗体の選択方法
WO2022037682A1 (fr) * 2020-08-21 2022-02-24 Hifibio (Shanghai) Limited Criblage fonctionnel au moyen de la microfluidique à gouttelettes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04234987A (ja) * 1990-12-28 1992-08-24 Mitsubishi Kasei Corp Ｄｎａ断片
US20140072979A1 (en) * 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
EP1392859B1 (fr) * 2001-01-16 2006-05-10 Regeneron Pharmaceuticals, Inc. Isolement de cellules exprimant des proteines secretees
EP1420803A1 (fr) * 2001-08-08 2004-05-26 Board Of Regents, The University Of Texas System Procede permettant d'amplifier l'expression a partir d'un promoteur a specificite cellulaire
EP2617827A1 (fr) * 2007-03-26 2013-07-24 Celexion, LLC Affichage de surface cellulaire, criblage et production de protéines d'intérêt
WO2009103753A1 (fr) * 2008-02-20 2009-08-27 Ablynx Nv Procédés d'identification et/ou de tri de cellules par molécule sécrétée et coffrets pour la mise en œuvre de tels procédés
JP2009268399A (ja) * 2008-05-07 2009-11-19 Tosoh Corp 抗体に結合可能な蛋白質発現ミエローマおよびこれを用いる細胞融合方法並びに交雑細胞およびその選別方法
CN102282266A (zh) * 2008-11-21 2011-12-14 德根生物科技有限公司 高复杂度哺乳动物展示文库及其筛选方法
CN107459577A (zh) * 2010-12-01 2017-12-12 默沙东公司 表面锚定的fc‑诱饵抗体展示系统
JP6277190B2 (ja) * 2012-08-21 2018-02-07 メディテクト アーベー 改善された細胞の同定のための方法
US9487773B2 (en) * 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection

Also Published As

Publication number Publication date
KR20190129062A (ko) 2019-11-19
WO2018167481A1 (fr) 2018-09-20
GB201704115D0 (en) 2017-04-26
CN110382548A (zh) 2019-10-25
AU2018234291A1 (en) 2019-10-31
JP2020510438A (ja) 2020-04-09
EP3596128A1 (fr) 2020-01-22
JP2024001060A (ja) 2024-01-09
KR102499955B1 (ko) 2023-02-14
US20200072820A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
SG11201804162WA (en) Compositions comprising bacterial strains
SG11201804211YA (en) Compositions comprising bacterial strains
SG11201807369UA (en) System and method for beam adjustment request
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201906341XA (en) Improved serum albumin binders
SG11201906264YA (en) Improved serum albumin binders
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201805253SA (en) Compositions and methods related to multimodal therapeutic cell systems for cancer indications
SG11201810013WA (en) Systems and methods for rapid prediction of hydrogen-induced cracking (hic) in pipelines, pressure vessels, and piping systems and for taking action in relation thereto
SG11201811184UA (en) Lag -3 binding members
SG11201804118VA (en) Compositions comprising bacterial strains
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201908675PA (en) Computer-implemented system and method for performing transaction mixing on a blockchain
SG11201808797XA (en) T cell receptors
CA3015496A1 (fr) Commande vocale d'un systeme de lecture multimedia
SG11201811095UA (en) Multi-level storage in ferroelectric memory
SG11201903693QA (en) Polypeptide variants and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201908470UA (en) Enzymatic production of hexoses
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201911572YA (en) Adenoviral vectors
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201907925WA (en) Method of selecting for antibodies